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ABSTRACT  
 
Objective: The objective of this selective evidence-based medicine (EBM) review is to 
determine whether or not the combined oral contraceptive treatment of 150 mcg levonorgestrel 
and 30 mcg ethinyl estradiol is effective in preventing unscheduled uterine bleeding.  
 
Study Design: Review of two randomized controlled trials (RCTs) and one post hoc analysis, 
published after 2014 all in the English language.  
 
Data Sources: Two randomized controlled trials (RCTs)  
and one post hoc analysis, all of which evaluate the efficacy of the combined oral contraceptive 
(COC) treatment of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol in preventing 
bothersome unscheduled uterine bleeding. In both RCTs, an experimental group is compared to a 
control group receiving an identical appearing placebo. All studies were found using PubMed.  
 
Outcomes Measured: Each of the three articles analyzed the effects of the combined oral 
contraceptive of levonorgestrel and ethinyl estradiol in preventing bothersome unscheduled 
uterine bleeding. A five-point Likert Scale and bleeding diaries were the methods used to 
measure bothersome unscheduled uterine bleeding.  
 
Results: In the studies by Guiahi et al.2 and Hou et al.6, participants receiving the treatment of 
combined oral contraceptive showed statistically significant reduction in unscheduled uterine 
bleeding compared to the control group with p-values of <0.01 (Guiahi) and 0.03 (Hou). The 
study by Nappi et al.7 compared participants with 0-6 and >6 days of bleeding and showed 
significant improvement that increased each 91-day cycle of the combined oral contraceptive 
treatment with a confidence interval of 95% and an odds ratio (OR) of 1.531.  
 
Conclusions: Based on the systematic review of the two randomized controlled trials and one 
post hoc analysis, one can decisively say that 150 mcg levonorgestrel and 30 mcg ethinyl 
estradiol is effective in treating bothersome unscheduled uterine bleeding. All three studies 
verified statistically significant reduction in bleeding with use of the therapy.  
 
Keywords: Combined oral contraceptive, uterine bleeding, levonorgestrel, ethinyl estradiol, and 
unscheduled bleeding.  
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INTRODUCTION  
Unscheduled uterine bleeding is defined as any bleeding that occurs while using active 
contraceptive hormones, excluding bleeding that begins in the hormone-free interval and 
continues through days one to four of the subsequent active cycle. 1 A common reason why 
women often choose to discontinue hormonal contraception is dissatisfaction with its effects of 
uterine bleeding. Interventions that prevent or treat unscheduled bleeding could improve 
contraceptive acceptability and increase compliance, thus leading to fewer unplanned 
pregnancies.1  
In clinical trials, up to 11.3% of women report discontinuation of contraceptives for 
bothersome bleeding that is ultimately considered unacceptable.2 The bleeding pattern most 
bothersome to women is unscheduled bleeding or spotting and can occur with all hormonal 
methods of contraception.1 Prior to initiation of a contraceptive, healthcare providers should 
thoroughly counsel women about the range of bleeding patterns associated with its use. 
Providing this education will increase adherence to the method of contraception and reassure 
women that if used as directed, unscheduled uterine bleeding does not mean the method is 
ineffective at preventing pregnancy.1 However, proper adherence to the method of contraception 
does not ensure that bothersome unscheduled uterine bleeding will not continue to occur, causing 
women to seek treatment from their healthcare provider.  
Seeking a prescribed form of contraceptive requires a minimum of one annual visit for 
initiation or maintenance of the contraception. 3 Women should be instructed by their provider to 
follow up at any point to discuss side effects or complications. A complication such as 
unscheduled bleeding will increase the number of required annual visits for women who seek 
treatment.3 There are large differences in cost between different methods of hormonal 
contraception, with prescription contraceptives being the most expensive due to requiring 
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medical supervision.4 Implants, such as Nexplanon, cost over $800 each.5 Intrauterine devices, 
such as the Mirena and ParaGard, cost over $1,000 each. The cost of birth control pills is around 
$20 to $50 per pack with monthly purchases adding up to a yearly sum of $240 to $600. The 
Depo-Provera shot is $60 each with a total of around $240 per year. NuvaRing totals to 
approximately $1,000 per year.5 Since all methods of contraception can result in unscheduled 
bleeding, birth control pills are by far one of the most cost-effective options for women seeking 
treatment.1,5 
The pathogenesis of unscheduled bleeding in women using hormonal contraception is 
poorly understood.1 Unscheduled uterine bleeding is thought to be due to a relatively thick 
endometrium transitioning to a relatively thin endometrium as a result of the progestin-dominant 
component of all hormonal contraceptives.1 Many women find it acceptable to wait for 
spontaneous resolution of the problem. For those women who seek an intervention, a 
monophasic low-dose combined oral contraceptive (COC) is prescribed.  Currently there is no 
data supporting one low dose COC over another for this indication. 1,2 However, COCs are 
shown to effectively interrupt unscheduled uterine bleeding during treatment.1,2 This paper 
focuses on two randomized controlled trials (RCTs) and one post hoc analysis to evaluate the 
efficacy of a combined oral contraceptive treatment to prevent unscheduled uterine bleeding. 
 
OBJECTIVE  
The objective of this selective evidence-based medicine review is to determine whether 
or not the combined oral contraceptive treatment of 150 mcg levonorgestrel and 30 mcg ethinyl 
estradiol is effective in preventing unscheduled uterine bleeding.  
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METHODS 
The studies used in this systematic review included two randomized controlled trials that 
were both double-blind and placebo-controlled, and one post hoc analysis. The population 
studied includes women seeking intervention for complaints of bothersome unscheduled uterine 
bleeding or bleeding irregularity unrelated to an anatomical or organic source. The intervention 
used in each study is a combined oral contraceptive of 150 mcg levonorgestrel and 30 mcg 
ethinyl estradiol. Each of the randomized controlled trials utilized an experimental group 
receiving an identical appearing placebo as the comparison to the intervention. The post hoc 
analysis compared participants who experienced 0-6 days and >6 days of bleeding with each 91-
day cycle of the treatment. The outcome measured in each study includes the efficacy of the 
intervention in providing improvement of unscheduled uterine bleeding.  
All studies were discovered in the PubMed database using the key words “combined oral 
contraceptive,” “uterine bleeding,” “levonorgestrel and ethinyl estradiol,” and “unscheduled 
bleeding.”  Each article was published in the English language and in peer-reviewed journals. 
Articles were selected based on their relevance to the clinical question and if they included 
patient-oriented evidence that matters (POEMS). Inclusion criteria included studies that were 
randomized, controlled, and double-blind. Exclusion criteria included studies dated prior to 
2007, studies with women under the age of fourteen, and studies with women who were not 
experiencing uncontrolled bothersome uterine bleeding. Statistics reported in this review include 
number needed to treat (NNT), p-values, control event rate (CER), experimental event rate 
(EER), relative risk reduction (RRR), absolute risk reduction (ARR), odds ratio (OR), and 
confidence interval (CI). The demographics and characteristics specific to each study can be 
found in Table 1. 
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Table 1 - Demographics & Characteristics of included studies  
Study  Type # 
PTs  
Age 
(yrs)  
Inclusion Criteria Exclusion Criteria W/D Interventions  
Guiahi2 
(2015) 
RCT 32 18-
44 
Women who were 
English or Spanish 
speaking with a 
bleeding episode of 
at least 7 
consecutive days at 
the time of 
enrollment  
Women category 
3-4 for estrogen 
therapy, BMI >35, 
BP >135/85 
mmHg on more 
than 2 occasions, 
+pregnancy test, 
+chlamydia test, 
unable to swallow 
pills, severe 
medical 
conditions, taking 
hepatic enzyme 
inducing 
medications, 
allergy to COC, 
anatomic source of 
bleeding  
0 Levonorgestrel 
150 mcg and 
Ethinyl 
Estradiol 30 
mcg for 14 
days  
Hou6 
(2016) 
RCT 26 17-
34 
Women over the age 
of 14 who had 
requested 
intervention for 
complaints of 
significant bleeding 
irregularity or heavy 
flow.  
Women category 
3-4 for estrogen, 
previous treatment 
for bleeding with 
an etonogestrel 
implant, 
orthostatic vitals, 
organic causes for 
the bleeding   
2 Levonorgestrel 
150 mcg and 
Ethinyl 
Estradiol 30 
mcg for 28 
days  
Nappi7 
(2017) 
Post 
hoc 
anal-
ysis  
799 18-
40 
Sexually active adult 
women seeking 
COC as primary 
birth control, 
switching from 
another COC 
regimen, no prior 
history of COC use, 
women without any 
COC use in the last 
6 months 
Active smokers 
who were older 
than 35.  
112  Levonorgestrel 
150 mcg and 
Ethinyl 
Estradiol 30 
mcg in 91- day 
cycles over 1-
year low dose 
ethinyl 
estradiol in 
replacement of 
the normal 7-
day hormone 
free period 
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OUTCOMES MEASURED  
 The outcome measured in each of the studies was the amount of bleeding experienced by 
the participants both in the experimental and control groups. Guiahi et al. measured bleeding by 
having participants complete a bleeding and pill-taking diary.2 In the diary, participants recorded 
if the pill was taken on the appropriate day, the time the pill was taken each day, and the amount 
of bleeding experienced on a scale of none, spotting, light, normal or heavy.2 Hou et al. reported 
changes in bleeding during the last week of the study using a 5-point Likert scale.6 The scale 
included bleeding that improved significantly, improved slightly, no change, worsened slightly, 
or worsened significantly.6 Nappi et al. required participants to record bleeding and spotting 
episodes daily using electronic diaries with preprogrammed questions.7 Bleeding was defined as 
vaginal blood loss requiring sanitary protection. Spotting was defined as vaginal blood loss that 
did not require sanitary protection. Women could only enter information for a given day between 
12:00AM and 11:59PM. The electronic diary included an alarm set to the scheduled pill time and 
served as a reminder to complete the diary.7 
RESULTS  
Two randomized controlled trials and one post hoc analysis were used to determine if the 
combined oral contraceptive treatment of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol is 
effective in preventing unscheduled uterine bleeding. In each of the randomized controlled trials, 
the continuous data was able to be converted to dichotomous data. However, in the post hoc 
analysis study, the continuous data was not able to be converted. 
The randomized controlled trial conducted by Guiahi et al. included 32 women of similar 
demographic and reproductive characteristics, all of which reported having bleeding that was 
extremely or very annoying.2 See Table 1 for the study’s inclusion and exclusion criteria. The 
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women were divided equally into groups either receiving 14 days of the oral contraceptive or an 
identically appearing placebo. Throughout the study, each participant completed a daily bleeding 
and pill taking diary to ensure compliance to the study. Only one participant in the oral 
contraceptive arm was noncompliant with protocol by missing a pill on days 11 and 12 and 
taking two pills on days 13 and 14.2 Intent to treat analysis was performed and there was no loss 
to follow-up in the study. No adverse events were reported by any of the participants during the 
study. The primary outcome measured on completion of the study was temporary interruption of 
bleeding during therapy. Out of the participants in the experimental group receiving 14 days of a 
combined oral contraceptive containing 150 mcg levonorgestrel and 30 mcg ethinyl estradiol, 14 
out of 16 participants (87.5%) admitted to interruption of bleeding compared to 6 out of 16 
participants ( 37.5%) receiving an identical placebo.2  The study determined that participants 
receiving the oral contraceptive were 11.7 times more likely than the placebo group to have 
temporary interruption of bleeding.2  The study was determined to be statistically significant with 
a p-value <0.01 and a confidence interval (CI) of 95%. The results calculated from this 
randomized controlled trial are summarized in Table 2.  
Table 2- Efficacy of the COC in preventing unscheduled uterine bleeding, Guiahi et al.2 
CER EER RRR ARR NNT 
0.375 0.875 1.33 0.5 2.0 
Confidence Interval (CI)= 95% p-value= <0.01 
 
Hou et al. conducted a double-blind, placebo-controlled, randomized controlled trial on 
26 women reporting troublesome bleeding.6 The women were divided into an experimental 
group receiving a combined oral contraceptive of 150 mcg levonorgestrel and 30 mcg ethinyl 
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estradiol or an identical placebo for twenty-eight days. See Table 1 for the study’s inclusion and 
exclusion criteria. On days 22-28 of the study, the participants were asked to attend a follow up 
visit to inform the study staff if the treatment had improved bleeding using a 5-point Likert scale. 
In both the experimental and control groups, 12 out of 13 women returned for follow up. In the 
group receiving the combined oral contraceptive, 11 (92%) noted significant improvement in 
bleeding compared to 5 (42%) receiving the placebo.6 The study was determined to be 
statistically significant with a p-value of 0.03. Losses to follow-up for the study was determined 
to be <20% since 24 out of 26 participants completed the study. The results calculated from this 
randomized controlled trial are summarized in Table 3. Adverse events reported in the study 
included headache (n=10), nausea or vomiting (n=3), cramping (n=3), and breast tenderness 
(n=4).6  
Table 3- Efficacy of the COC in preventing unscheduled uterine bleeding, Hou et al.6 
CER EER RRR ARR NNT 
0.42 0.92 1.19 0.5 2.0 
p-value= 0.03 
  
The post hoc analysis of a multicenter, open-label, 1-year, Phase 3 study conducted by 
Nappi et al. evaluated scheduled and unscheduled bleeding and spotting with the thought that 
ovarian suppression may result in improved cycle control and reduced risk of unscheduled 
bleeding.7 The study was conducted over one year with all participants receiving the treatment of 
a 91-day extended regimen of the combined oral contraception 150 mcg levonorgestrel and 30 
mcg ethinyl estradiol for 84 days, and ethinyl estradiol 10 mcg in place of the traditional 7-day 
hormone-free interval.7 The study observed 799 women who completed at least one 91-day cycle 
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of therapy and reported their bleeding and spotting episodes using daily electronic diaries.7 See 
Table 1 for the study’s inclusion and exclusion criteria. Table 4 summarizes the percentage of 
women for each cycle completed that reported unscheduled bleeding lasting less than six days or 
greater than six days. There was a 53% increase in the likelihood of women reporting 0-6 days 
versus greater than 6 days of unscheduled bleeding during days 1-84 for each additional 91-day 
cycle. The results led to an odds ratio (OR) of 1.531 and a confidence interval (CI) of 95% 
shown in Table 5.7 It was reported that there were more than one in five women reporting no 
bleeding by the third and fourth cycles of the study. Examination of study discontinuation 
showed 10% (80/799) discontinued due to an adverse event with 4% (32/799) due to bleeding 
and spotting adverse effects. The safety of this extended regimen combined oral contraceptive 
treatment is supported in that there was no accumulation of hormones, no unexpected changes to 
the endometrium, no effect of cycle length on hemostatic biomarkers, and similar incidence rates 
of adverse events over four years of continuous use compared with the conventional 28-day 
cycle.  
Table 4- Percent of women reporting unscheduled bleeding, Nappi et al.7 
Days of bleeding Cycle 1 
n=758 
Cycle 2 
n=625 
Cycle 3 
n=533 
Cycle 4 
n=446 
0-6 Days 65% 81% 85% 85% 
>6 Days 35% 19% 15% 15% 
*n= number of participants for each cycle  
Table 5- Efficacy of the COC in preventing unscheduled uterine bleeding, Nappi et al.7 
Odds Ratio (OR) Confidence Interval (CI) 
1.531 95% 
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DISCUSSION  
 The two randomized controlled trials and post hoc analysis discussed in this systematic 
review determined the efficacy of a combined oral contraceptive’s ability to treat bothersome 
unscheduled uterine bleeding. All three studies showed significant improvement of unscheduled 
bleeding with either minimal or no adverse events. Each study demonstrated statistically 
significant outcomes with p-values of <0.01, 0.03, or confidence intervals of 95%. 2,6,7  
 It is important to note that the studies done by Guiahi et al. and Hou et al. included 
participants that along with receiving the combined oral contraceptive during the study, also had 
an etonogestrel contraceptive implant with which they were experiencing bothersome uterine 
bleeding.2,6 Participants in the study conducted by Nappi et al. did not have an etonogestrel 
implant during the study.7  
 The combined oral contraceptive levonorgestrel and ethinyl estradiol is primarily used for 
the prevention of pregnancy.8 Some off-label uses include abnormal uterine bleeding, 
dysmenorrhea, hirsutism, menorrhagia, pain associated with endometriosis, and polycystic ovary 
syndrome (PCOS).8 Contraindications to usage include breast cancer or other estrogen or 
progestin dependent neoplasms, hepatic tumor or disease, pregnancy, and Hepatitis C drug 
combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.  8 It is also 
contraindicated in women at high risk of arterial or venous thrombotic diseases. The US boxed 
warnings for levonorgestrel and ethinyl estradiol include cigarette smoke and cardiovascular 
events.8 
 There were several limitations to the studies used in this review. The study conducted by 
Guiahi et al. had a limited protocol in which the first day of bleeding after therapy was the end of 
that individual’s participation in the study.2 This prevented the study from reporting on the long-
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term bleeding patterns after a single 14-day treatment. A larger study would be needed to 
confirm the results of the sample and to determine if any patient characteristics influence 
success. Due to the small sample size in the study by Hou et al., the study population was too 
small for substantial subgroup and regression analyses.6 Since the study only included women 
seeking treatment for their bleeding, it did not represent all women who have a bleeding issue 
with the etonogestrel implant, but instead those who have more extreme bleeding complaints 
creating another limitation to this study. Limitations to the study by Nappi et al. include its open-
label design and lack of a comparison group for evaluation of change in bleeding over time.7 The 
study also lacked correction to unscheduled bleeding/spotting when missed pill episodes were 
reported. 
CONCLUSIONS 
 Based on the current research available, it can be determined that yes, the combined oral 
contraceptive of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol is effective in treating 
bothersome, unscheduled uterine bleeding. All three studies in this review demonstrated 
statistically significant data that supported improvement in bleeding for participants receiving the 
combined oral contraceptive treatment. 2,6,7 A flaw in the methods used by these studies that 
could be corrected in future studies is finding a less subjective way to monitor the amount of 
bleeding experienced by the participants. For example, bleeding that is considered heavy to one 
participant may be normal to another. Future study is warranted to further evaluate the long-term 
acceptability of bleeding, and length of the treatment’s effect, after use of combined oral 
contraceptives to treat bothersome bleeding episodes.  
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